GAB1 has been described to be involved in alectinib resistance mediated by activation of the HGF/MET signaling pathway in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer [130]. This evidence concerns the gene ALK and non-small cell lung carcinoma.